{"id":1284381,"date":"2024-08-15T08:29:55","date_gmt":"2024-08-15T02:59:55","guid":{"rendered":"https:\/\/trak.in\/stories\/?p=1284381"},"modified":"2024-08-15T08:30:17","modified_gmt":"2024-08-15T03:00:17","slug":"1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine","status":"publish","type":"post","link":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/","title":{"rendered":"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine!"},"content":{"rendered":"\n

In a significant step toward combating dengue, India has commenced its first Phase III clinical trial for an indigenous dengue vaccine named “DengiAll.” Developed by Panacea Biotech, this vaccine is designed to protect against all four serotypes of the dengue virus, marking a crucial advancement in the country’s efforts to tackle the pervasive disease. The trial<\/a> was launched on Wednesday, with the first dose administered at Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences (PGIMS) in Rohtak.<\/p>\n\n\n\n

\"1st<\/figure>\n\n\n\n

Comprehensive Trial Across India<\/strong><\/h4>\n\n\n\n

The Phase III trial is expansive, covering 19 sites across 18 states and Union Territories. Over the next two years, it will monitor 10,335 healthy adults to evaluate the vaccine’s efficacy and safety. This extensive trial is primarily funded by the Indian Council of Medical Research (ICMR), with Panacea Biotech also contributing to the costs. The trial represents a collaborative effort between the Indian government and the private sector, emphasizing the importance of public health in India\u2019s national agenda.<\/p>\n\n\n\n

Innovative Vaccine Technology<\/strong><\/h4>\n\n\n\n

The DengiAll vaccine utilizes live, weakened versions of all four dengue serotypes, a complex and innovative approach that addresses the challenge of dengue\u2019s multiple serotypes. These weakened viruses were developed by the National Institute of Allergy and Infectious Diseases (NIAID) in the United States. The NIAID\u2019s technology involved deleting parts of the genetic code from three dengue serotypes (DENV1, DENV3, and DENV4) and then genetically engineering these onto a DENV2 backbone. This technology was crucial in overcoming one of the significant hurdles in dengue vaccine development\u2014ensuring protection across all four serotypes without increasing the risk of severe disease.<\/p>\n\n\n\n

Addressing Challenges in Dengue Vaccination<\/strong><\/h4>\n\n\n\n

Developing a dengue vaccine has been notoriously challenging due to the virus’s ability to infect individuals multiple times, with each serotype offering little protection against the others. This can lead to antibody-dependent enhancement (ADE), where a person with low levels of antibodies against one serotype may experience a more severe infection when exposed to another. The issue of ADE has been central to controversies surrounding earlier dengue vaccines. The DengiAll trial is, therefore, a critical step in ensuring that India\u2019s vaccine not only provides broad protection but does so safely.<\/p>\n\n\n\n

India’s Growing Vaccine Capabilities<\/strong><\/h4>\n\n\n\n

The launch of this trial underscores India\u2019s growing capabilities in vaccine research and development. Union Health Minister JP Nadda highlighted this achievement as a testament to India\u2019s commitment to protecting its citizens from dengue. As the trial progresses, it will serve as a pivotal moment in India\u2019s public health efforts, potentially paving the way for a widely accessible and effective dengue vaccine in the near future.<\/p>\n\n\n\n

4o<\/p>\n","protected":false},"excerpt":{"rendered":"

In a significant step toward combating dengue, India has commenced its first Phase III clinical trial for an indigenous dengue vaccine named “DengiAll.” Developed by Panacea Biotech, this vaccine is designed to protect against all four serotypes of the dengue virus, marking a crucial advancement in the country’s efforts to tackle the pervasive disease. The […]<\/p>\n","protected":false},"author":30,"featured_media":1284389,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[401],"tags":[5886],"class_list":["post-1284381","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-healthcare","tag-dengue-vaccine"],"acf":[],"yoast_head":"\n1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"og:description\" content=\"In a significant step toward combating dengue, India has commenced its first Phase III clinical trial for an indigenous dengue vaccine named “DengiAll.” Developed by Panacea Biotech, this vaccine is designed to protect against all four serotypes of the dengue virus, marking a crucial advancement in the country’s efforts to tackle the pervasive disease. The […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/\" \/>\n<meta property=\"og:site_name\" content=\"Trak.in - Indian Business of Tech, Mobile & Startups\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-15T02:59:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-15T03:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM-1024x575.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"575\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Mohul Ghosh\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mohul Ghosh\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/\",\"url\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/\",\"name\":\"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups\",\"isPartOf\":{\"@id\":\"https:\/\/trak.in\/stories\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png\",\"datePublished\":\"2024-08-15T02:59:55+00:00\",\"dateModified\":\"2024-08-15T03:00:17+00:00\",\"author\":{\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\"},\"breadcrumb\":{\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage\",\"url\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png\",\"contentUrl\":\"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png\",\"width\":1990,\"height\":1118},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/trak.in\/stories\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/trak.in\/stories\/#website\",\"url\":\"https:\/\/trak.in\/stories\/\",\"name\":\"Trak.in - Indian Business of Tech, Mobile & Startups\",\"description\":\"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/trak.in\/stories\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7\",\"name\":\"Mohul Ghosh\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g\",\"caption\":\"Mohul Ghosh\"},\"url\":\"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/","og_locale":"en_US","og_type":"article","og_title":"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups","og_description":"In a significant step toward combating dengue, India has commenced its first Phase III clinical trial for an indigenous dengue vaccine named “DengiAll.” Developed by Panacea Biotech, this vaccine is designed to protect against all four serotypes of the dengue virus, marking a crucial advancement in the country’s efforts to tackle the pervasive disease. The […]","og_url":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/","og_site_name":"Trak.in - Indian Business of Tech, Mobile & Startups","article_published_time":"2024-08-15T02:59:55+00:00","article_modified_time":"2024-08-15T03:00:17+00:00","og_image":[{"width":1024,"height":575,"url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM-1024x575.png","type":"image\/png"}],"author":"Mohul Ghosh","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Mohul Ghosh","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/","url":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/","name":"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine! - Trak.in - Indian Business of Tech, Mobile & Startups","isPartOf":{"@id":"https:\/\/trak.in\/stories\/#website"},"primaryImageOfPage":{"@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage"},"image":{"@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage"},"thumbnailUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png","datePublished":"2024-08-15T02:59:55+00:00","dateModified":"2024-08-15T03:00:17+00:00","author":{"@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7"},"breadcrumb":{"@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#primaryimage","url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png","contentUrl":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png","width":1990,"height":1118},{"@type":"BreadcrumbList","@id":"https:\/\/trak.in\/stories\/1st-time-ever-phase-3-clinical-trials-of-dengue-vaccine-starts-100-made-in-india-vaccine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/trak.in\/stories\/"},{"@type":"ListItem","position":2,"name":"1st Time Ever, Phase 3 Clinical Trials Of Dengue Vaccine Starts: 100% Made In India Vaccine!"}]},{"@type":"WebSite","@id":"https:\/\/trak.in\/stories\/#website","url":"https:\/\/trak.in\/stories\/","name":"Trak.in - Indian Business of Tech, Mobile & Startups","description":"Trak.in is a popular Indian Business, Technology, Mobile & Startup blog featuring trending News, views and analytical take on Technology, Business, Finance, Telecom, Mobile, startups & Social Media Space","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/trak.in\/stories\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/5092a7d2906e3f3c819643435477c2a7","name":"Mohul Ghosh","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/trak.in\/stories\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/66c129d83dd3f325a3b550eb1aa16891173ddfc4686361424206cd9a01311c89?s=96&d=mm&r=g","caption":"Mohul Ghosh"},"url":"https:\/\/trak.in\/stories\/author\/mohul-ghosh\/"}]}},"jetpack_featured_media_url":"https:\/\/trak.in\/stories\/wp-content\/uploads\/2024\/08\/Screenshot-2024-08-15-at-8.28.59\u202fAM.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1284381","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/comments?post=1284381"}],"version-history":[{"count":1,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1284381\/revisions"}],"predecessor-version":[{"id":1284390,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/posts\/1284381\/revisions\/1284390"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media\/1284389"}],"wp:attachment":[{"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/media?parent=1284381"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/categories?post=1284381"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trak.in\/stories\/wp-json\/wp\/v2\/tags?post=1284381"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}